Timothy Davis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7539691/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	13.7	1,625
2	Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet, The, 2007, 370, 1687-1697.	13.7	918
3	Plasmodium knowlesi Malaria in Humans Is Widely Distributed and Potentially Life Threatening. Clinical Infectious Diseases, 2008, 46, 165-171.	5.8	676
4	Melioidosis: A Major Cause of Community-Acquired Septicemia in Northeastern Thailand. Journal of Infectious Diseases, 1989, 159, 890-899.	4.0	515
5	Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes/Metabolism Research and Reviews, 2007, 23, 3-13.	4.0	411
6	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	13.7	394
7	Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 2011, 54, 280-290.	6.3	304
8	Clinical and Laboratory Features of Human <i>Plasmodium knowlesi</i> Infection. Clinical Infectious Diseases, 2009, 49, 852-860.	5.8	277
9	Glycemic Exposure Is Associated With Reduced Pulmonary Function in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2004, 27, 752-757.	8.6	262
10	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet, The, 2021, 398, 1811-1824.	13.7	257
11	Piperaquine. Drugs, 2005, 65, 75-87.	10.9	247
12	Reappraisal of known malaria resistance loci in a large multicenter study. Nature Genetics, 2014, 46, 1197-1204.	21.4	206
13	Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal of Tropical Medicine and Hygiene, 2014, 91, 833-843	1.4	204
14	Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus. Circulation, 2014, 129, 999-1008.	1.6	197
15	Peripheral Arterial Disease and Risk of Cardiac Death in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2006, 29, 575-580.	8.6	195
16	Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the Fremantle Diabetes Study. Diabetologia, 2009, 52, 1808-1815.	6.3	191
17	A Trial of Combination Antimalarial Therapies in Children from Papua New Guinea. New England Journal of Medicine, 2008, 359, 2545-2557.	27.0	174
18	Risk Factors for Stroke in Type 2 Diabetes Mellitus. Archives of Internal Medicine, 1999, 159, 1097.	3.8	173

2

#	Article	IF	CITATIONS
19	Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia, 2011, 54, 32-43.	6.3	172
20	Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nature Genetics, 2012, 44, 1375-1381.	21.4	169
21	Effect of a Pharmaceutical Care Program on Vascular Risk Factors in Type 2 Diabetes. Diabetes Care, 2005, 28, 771-776.	8.6	156
22	Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia, 2008, 51, 562-566.	6.3	149
23	Determinants of Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2240-2247.	3.6	148
24	Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. British Journal of Clinical Pharmacology, 2003, 57, 253-262.	2.4	146
25	Glucuronidation of Dihydroartemisinin in Vivo and by Human Liver Microsomes and Expressed UDP-Glucuronosyltransferases. Drug Metabolism and Disposition, 2002, 30, 1005-1012.	3.3	138
26	Efficacy and Safety of Dihydroartemisininâ€₽iperaquine (Artekin) in Cambodian Children and Adults with Uncomplicated Falciparum Malaria. Clinical Infectious Diseases, 2002, 35, 1469-1476.	5.8	136
27	Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: The Fremantle Diabetes Study. Diabetologia, 2006, 49, 2634-2641.	6.3	135
28	Artemisininâ€based combination therapies for uncomplicated malaria. Medical Journal of Australia, 2005, 182, 181-185.	1.7	133
29	Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Fremantle Cognition in Diabetes Study. Diabetes Research and Clinical Practice, 2003, 61, 59-67.	2.8	124
30	Longitudinal Predictors of Reduced Mobility and Physical Disability in Patients With Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2005, 28, 2441-2447.	8.6	124
31	Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia, 2008, 51, 241-248.	6.3	123
32	A prospective study of depression and mortality in patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetologia, 2005, 48, 2532-2539.	6.3	117
33	Growth Hormone (GH) Release in Response to GH-Releasing Hormone in Man is 3-Fold Enhanced by Galanin*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 1248-1252.	3.6	115
34	Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2000, 50, 153-159.	2.8	114
35	Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabetic Medicine, 2000, 17, 667-674.	2.3	113
36	Selective high-performance liquid chromatographic determination of artesunate and α- and β-dihydroartemisinin in patients with falciparum malaria. Biomedical Applications, 1996, 677, 345-350.	1.7	112

#	Article	IF	CITATIONS
37	Prevalence and progression of subclinical hypothyroidism in women with typeÂ2 diabetes: the Fremantle Diabetes Study. Clinical Endocrinology, 2005, 62, 480-486.	2.4	111
38	Cohort Profile: The Fremantle Diabetes Study. International Journal of Epidemiology, 2013, 42, 412-421.	1.9	111
39	CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovascular Diabetology, 2021, 20, 154.	6.8	111
40	In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. International Journal for Parasitology, 1996, 26, 519-525.	3.1	110
41	Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Medical Journal of Australia, 2007, 186, 461-465.	1.7	110
42	Diabetes education and knowledge in patients with type 2 diabetes from the community. Journal of Diabetes and Its Complications, 2003, 17, 82-89.	2.3	109
43	Interactions among Thyroid Function, Insulin Sensitivity, and Serum Lipid Concentrations: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5317-5320.	3.6	108
44	Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment. Diabetes Care, 2012, 35, 218-225.	8.6	108
45	A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. British Journal of Clinical Pharmacology, 1998, 45, 123-129.	2.4	105
46	Comparative Pharmacokinetics of Intramuscular Artesunate and Artemether in Patients with Severe Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2004, 48, 4234-4239.	3.2	105
47	Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. European Heart Journal, 2010, 31, 92-99.	2.2	105
48	Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia, 2005, 48, 695-702.	6.3	101
49	Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin [®]) in Cambodian children and adults with malaria. British Journal of Clinical Pharmacology, 2004, 57, 93-99.	2.4	99
50	Prognostic Significance of Silent Myocardial Infarction in Newly Diagnosed Type 2 Diabetes Mellitus. Circulation, 2013, 127, 980-987.	1.6	99
51	Acute Suppurative Parotitis Caused by Pseudomonas pseudomallei in Children. Journal of Infectious Diseases, 1989, 159, 654-660.	4.0	97
52	Relationship Between Ethnicity and Glycemic Control, Lipid Profiles, and Blood Pressure During the First 9 Years of Type 2 Diabetes: U.K. Prospective Diabetes Study (UKPDS 55). Diabetes Care, 2001, 24, 1167-1174.	8.6	97
53	Disposition of oral quinine in acute falciparum malaria. European Journal of Clinical Pharmacology, 1991, 40, 49-52.	1.9	96
54	Comparison of three antigen detection methods for diagnosis and therapeutic monitoring of malaria: a field study from southern Vietnam. Tropical Medicine and International Health, 2002, 7, 304-308.	2.3	96

#	Article	IF	CITATIONS
55	Predictors of Cognitive Decline in Older Individuals With Diabetes. Diabetes Care, 2008, 31, 2103-2107.	8.6	93
56	The Current Status and Potential Role of Laboratory Testing to Prevent Transfusion-Transmitted Malaria. Transfusion Medicine Reviews, 2005, 19, 229-240.	2.0	92
57	Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Severe Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2001, 45, 181-186.	3.2	90
58	Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study. Lancet Haematology,the, 2018, 5, e333-e345.	4.6	90
59	Bâ€vitamins reduce the longâ€ŧerm risk of depression after stroke: The VITATOPSâ€DEP trial. Annals of Neurology, 2010, 68, 503-510.	5.3	85
60	Negative Association between Infra-renal Aortic Diameter and Glycaemia: The Health In Men Study. European Journal of Vascular and Endovascular Surgery, 2007, 33, 599-604.	1.5	84
61	Effects of a High-Fat Meal on the Relative Oral Bioavailability of Piperaquine. Antimicrobial Agents and Chemotherapy, 2005, 49, 2407-2411.	3.2	83
62	ls Self-Monitoring of Blood Glucose Appropriate for All Type 2 Diabetic Patients?: The Fremantle Diabetes Study. Diabetes Care, 2006, 29, 1764-1770.	8.6	81
63	The IGSF1 Deficiency Syndrome: Characteristics of Male and Female Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4942-4952.	3.6	81
64	Pharmacokinetics and Efficacy of Piperaquine and Chloroquine in Melanesian Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2008, 52, 237-243.	3.2	80
65	Alpha 1â€acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria British Journal of Clinical Pharmacology, 1991, 32, 311-315.	2.4	79
66	Erythrocyte survival in severe falciparum malaria. Acta Tropica, 1991, 48, 263-270.	2.0	77
67	Bone mineral density and its determinants in diabetes: the Fremantle Diabetes Study. Diabetologia, 2006, 49, 863-871.	6.3	77
68	U.K. Prospective Diabetes Study 22: Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM. Diabetes Care, 1997, 20, 1435-1441.	8.6	76
69	Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes. Diabetic Medicine, 2009, 26, 45-52.	2.3	76
70	The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. British Journal of Pharmacology, 2000, 131, 756-760.	5.4	75
71	Features and Prognosis of Severe Malaria Caused by Plasmodium falciparum, Plasmodium vivax and Mixed Plasmodium Species in Papua New Guinean Children. PLoS ONE, 2011, 6, e29203.	2.5	74
72	A comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, insulin resistance and the metabolic syndrome. BMC Medical Genetics, 2013, 14, 15.	2.1	73

#	Article	IF	CITATIONS
73	Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study. Diabetologia, 2007, 50, 510-515.	6.3	71
74	Effect of Continuous Positive Airway Pressure Therapy on Cardiovascular Risk Factors in Patients with Type 2 Diabetes and Obstructive Sleep Apnea. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4212-4218.	3.6	70
75	Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. British Journal of Clinical Pharmacology, 2001, 51, 541-546.	2.4	68
76	Matrix Biology of Abdominal Aortic Aneurysms in Diabetes: Mechanisms Underlying the Negative Association. Connective Tissue Research, 2007, 48, 125-131.	2.3	67
77	Synthesis and antimalarial evaluation of novel isocryptolepine derivatives. Bioorganic and Medicinal Chemistry, 2011, 19, 7519-7525.	3.0	67
78	A study of the factors affecting the metabolic clearance of quinine in malaria. European Journal of Clinical Pharmacology, 1997, 52, 487-493.	1.9	66
79	Effect of insulin therapy on quality of life in Type 2 diabetes mellitus: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2001, 52, 63-71.	2.8	66
80	Pharmacokinetics of Chloroquine and Monodesethylchloroquine in Pregnancy. Antimicrobial Agents and Chemotherapy, 2010, 54, 1186-1192.	3.2	66
81	Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. British Journal of Clinical Pharmacology, 2000, 49, 223-230.	2.4	65
82	Pyrvinium Targets the Unfolded Protein Response to Hypoglycemia and Its Anti-Tumor Activity Is Enhanced by Combination Therapy. PLoS ONE, 2008, 3, e3951.	2.5	65
83	The value of self-monitoring of blood glucose: a review of recent evidence. Journal of Diabetes and Its Complications, 2010, 24, 129-141.	2.3	65
84	Î ³ δT cells and CD14+ Monocytes Are Predominant Cellular Sources of Cytokines and Chemokines Associated With Severe Malaria. Journal of Infectious Diseases, 2014, 210, 295-305.	4.0	65
85	A Sub-Microscopic Gametocyte Reservoir Can Sustain Malaria Transmission. PLoS ONE, 2011, 6, e20805.	2.5	65
86	Hemodynamic Effects of Fenofibrate and Coenzyme Q10 in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction. Diabetes Care, 2008, 31, 1502-1509.	8.6	63
87	An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study. Internal Medicine Journal, 2010, 40, 286-292.	0.8	63
88	Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study. Diabetologia, 2004, 47, 395-399.	6.3	62
89	Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia, 2010, 53, 1288-1294.	6.3	62
90	Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study. Medical Journal of Australia, 2006, 184, 325-328.	1.7	61

#	Article	IF	CITATIONS
91	Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. Medical Journal of Australia, 2008, 188, 446-449.	1.7	61
92	The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects British Journal of Clinical Pharmacology, 1995, 39, 305-311.	2.4	59
93	Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care, 2017, 40, 1548-1555.	8.6	59
94	Arrhythmias and Mortality After Myocardial Infarction in Diabetic Patients: Relationship to diabetes treatment. Diabetes Care, 1998, 21, 637-640.	8.6	58
95	Personality traits, selfâ€care behaviours and glycaemic control in TypeÂ2 diabetes: The Fremantle Diabetes Study PhaseÂ <scp>II</scp> . Diabetic Medicine, 2014, 31, 487-492.	2.3	58
96	A systematic review of risk factors for cataract in type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2019, 35, e3073.	4.0	58
97	Erythrocyte sequestration and anemia in severe falciparum malaria. Analysis of acute changes in venous hematocrit using a simple mathematical model Journal of Clinical Investigation, 1990, 86, 793-800.	8.2	57
98	Serum procalcitonin concentrations in acute malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 670-671.	1.8	56
99	A Safe and Effective Consecutive-Infusion Regimen for Rapid Quinine Loading in Severe Falciparum Malaria. Journal of Infectious Diseases, 1990, 161, 1305-1308.	4.0	55
100	The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. British Journal of Clinical Pharmacology, 2001, 52, 137-144.	2.4	55
101	Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 791, 93-101.	2.3	55
102	Measures of Capillary Permeability in Acute Falciparum Malaria: Relation to Severity of Infection and Treatment. Clinical Infectious Diseases, 1992, 15, 256-266.	5.8	53
103	Electrocardiographic monitoring in severe falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90, 266-269.	1.8	53
104	Pharmacokinetic Properties of Sulfadoxine-Pyrimethamine in Pregnant Women. Antimicrobial Agents and Chemotherapy, 2009, 53, 4368-4376.	3.2	53
105	Desbutyl-Lumefantrine Is a Metabolite of Lumefantrine with Potent <i>In Vitro</i> Antimalarial Activity That May Influence Artemether-Lumefantrine Treatment Outcome. Antimicrobial Agents and Chemotherapy, 2011, 55, 1194-1198.	3.2	53
106	Reduced Risk of Plasmodium vivax Malaria in Papua New Guinean Children with Southeast Asian Ovalocytosis in Two Cohorts and a Case-Control Study. PLoS Medicine, 2012, 9, e1001305.	8.4	53
107	Incidence and Predictors of Hospitalization for Bacterial Infection in Community-Based Patients with Type 2 Diabetes: The Fremantle Diabetes Study. PLoS ONE, 2013, 8, e60502.	2.5	53
108	A five-year prospective study of bone mineral density in men and women with diabetes: The Fremantle Diabetes Study. Acta Diabetologica, 2012, 49, 153-158.	2.5	52

#	Article	IF	CITATIONS
109	Lifetime depression and anxiety increase prevalent psychological symptoms and worsen glycemic control in type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes Research and Clinical Practice, 2016, 122, 190-197.	2.8	52
110	Penetration of Dihydroartemisinin into Cerebrospinal Fluid after Administration of Intravenous Artesunate in Severe Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2003, 47, 368-370.	3.2	51
111	Chronic complications and mortality in communityâ€based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study. Diabetic Medicine, 2008, 25, 1245-1250.	2.3	51
112	Disposition of Artesunate and Dihydroartemisinin after Administration of Artesunate Suppositories in Children from Papua New Guinea with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2004, 48, 2966-2972.	3.2	50
113	Magnetic susceptibility of iron in malaria-infected red blood cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 93-99.	3.8	50
114	Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malaria Journal, 2010, 9, 238.	2.3	50
115	Population Pharmacokinetics of Artemether, Lumefantrine, and Their Respective Metabolites in Papua New Guinean Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 5306-5313.	3.2	50
116	HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes. Diabetes Care, 2014, 37, 2351-2358.	8.6	50
117	Clucose turnover in severe falciparum malaria. Metabolism: Clinical and Experimental, 1993, 42, 334-340.	3.4	49
118	The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. British Journal of Clinical Pharmacology, 2002, 53, 23-30.	2.4	49
119	A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. International Journal of Pharmacy Practice, 2011, 10, 85-89.	0.6	48
120	Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability. PLoS ONE, 2014, 9, e102023.	2.5	48
121	Ethnicity and longâ€ŧerm vascular outcomes in TypeÂ2 diabetes: a prospective observational study (UKPDSÂ83). Diabetic Medicine, 2014, 31, 200-207.	2.3	48
122	Glycemic Control in Older Subjects with Type 2 Diabetes Mellitus in the Fremantle Diabetes Study. Journal of the American Geriatrics Society, 2000, 48, 1449-1453.	2.6	47
123	Continuing Disparities in Cardiovascular Risk Factors and Complications Between Aboriginal and Anglo-Celt Australians With Type 2 Diabetes. Diabetes Care, 2012, 35, 2005-2011.	8.6	47
124	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Medicine, 2018, 15, e1002579.	8.4	47
125	Artesunate Suppositories versus Intramuscular Artemether for Treatment of Severe Malaria in Children in Papua New Guinea. Antimicrobial Agents and Chemotherapy, 2006, 50, 968-974.	3.2	46
126	Prevalence and Risk Factor Correlates of Elevated C-Reactive Protein in an Adult Australian Population. American Journal of Cardiology, 2008, 101, 193-198.	1.6	46

#	Article	IF	CITATIONS
127	Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: a prospective cohort study. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 235-241.	2.8	46
128	A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society. Medical Journal of Australia, 2014, 201, 650-653.	1.7	46
129	Incidence and predictors of hospitalization for tendon rupture in Type 2 diabetes: the Fremantle Diabetes Study. Diabetic Medicine, 2014, 31, 425-430.	2.3	46
130	Comparison of anthropometric measures as predictors of cancer incidence: A pooled collaborative analysis of 11 <scp>A</scp> ustralian cohorts. International Journal of Cancer, 2015, 137, 1699-1708.	5.1	46
131	Prevalence of diabetes in Australia: insights from the Fremantle Diabetes Study Phase II. Internal Medicine Journal, 2018, 48, 803-809.	0.8	46
132	The Relationship between Hypomagnesemia, Metformin Therapy and Cardiovascular Disease Complicating Type 2 Diabetes: The Fremantle Diabetes Study. PLoS ONE, 2013, 8, e74355.	2.5	46
133	Rectal Administration of Artemisinin Derivatives for the Treatment of Malaria. JAMA - Journal of the American Medical Association, 2007, 297, 2381.	7.4	45
134	Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Medical Journal of Australia, 2009, 190, 180-184.	1.7	45
135	Dichloroacetate for lactic acidosis in severe malaria: A pharmacokinetic and pharmacodynamic assessment. Metabolism: Clinical and Experimental, 1994, 43, 974-981.	3.4	44
136	Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. British Journal of Clinical Pharmacology, 1996, 42, 415-421.	2.4	44
137	Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers. British Journal of Clinical Pharmacology, 2008, 65, 674-679.	2.4	43
138	Pharmacokinetic Properties of Azithromycin in Pregnancy. Antimicrobial Agents and Chemotherapy, 2010, 54, 360-366.	3.2	43
139	Dipeptidyl peptidaseâ€4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes, Obesity and Metabolism, 2014, 16, 891-899.	4.4	43
140	Fear of falling is common in patients with type 2 diabetes and is associated with increased risk of falls. Age and Ageing, 2015, 44, 687-690.	1.6	43
141	Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes and Endocrinology,the, 2018, 6, 310-318.	11.4	43
142	Resistance of Plasmodium falciparum to antimalarial drugs in a highly endemic area of southern Viet Nam: a study in vivo and in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 325-329.	1.8	42
143	Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial. Cardiovascular Diabetology, 2011, 10, 102.	6.8	42
144	Hepatic blood flow and metabolism in severe falciparum malaria: clearance of intravenously administered galactose. Clinical Science, 1992, 82, 63-70.	4.3	41

#	Article	IF	CITATIONS
145	Dementia and its associations in type 2 diabetes mellitus: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2001, 53, 165-172.	2.8	41
146	Nurse-based evaluation of point-of-care assays for glycated haemoglobin. Clinica Chimica Acta, 2006, 365, 257-263.	1.1	40
147	Severe Anemia in Papua New Guinean Children from a Malaria-Endemic Area: A Case-Control Etiologic Study. PLoS Neglected Tropical Diseases, 2012, 6, e1972.	3.0	40
148	Interactions among primaquine, malaria infection and other antimalarials in Thai subjects British Journal of Clinical Pharmacology, 1993, 35, 193-198.	2.4	39
149	Skeletal Muscle Involvement in Falciparum Malaria: Biochemical and Ultrastructural Study. Clinical Infectious Diseases, 1999, 29, 831-835.	5.8	39
150	Characteristics and outcome of type 2 diabetes in urban Aboriginal people: the Fremantle Diabetes Study. Internal Medicine Journal, 2007, 37, 59-63.	0.8	38
151	Effect of continuous positive airway pressure therapy on sexual function and serum testosterone in males with type 2 diabetes and obstructive sleep apnoea. Clinical Endocrinology, 2014, 81, 254-258.	2.4	38
152	The efficacy of a malarial antibody enzyme immunoassay for establishing the reinstatement status of blood donors potentially exposed to malaria. Vox Sanguinis, 2005, 88, 98-106.	1.5	37
153	Role of P Glycoprotein in Absorption of Novel Antimalarial Drugs. Antimicrobial Agents and Chemotherapy, 2006, 50, 3504-3506.	3.2	37
154	Ethnic diversity in Type 2 diabetes. Diabetic Medicine, 2008, 25, 52-56.	2.3	37
155	Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated TypeA2 diabetic patients. Clinical Science, 2010, 118, 607-615.	4.3	37
156	Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the Fremantle Diabetes Study. Cardiovascular Diabetology, 2015, 14, 152.	6.8	37
157	Anemia complicating type 2 diabetes: Prevalence, risk factors and prognosis. Journal of Diabetes and Its Complications, 2017, 31, 1169-1174.	2.3	37
158	Prospective Evaluation of Carotid Bruit as a Predictor of First Stroke in Type 2 Diabetes. Stroke, 2003, 34, 2145-2151.	2.0	36
159	Prevalence and prognostic implications of the metabolic syndrome in community-based patients with type 1 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2007, 78, 412-417.	2.8	36
160	Artemisinin-Naphthoquine Combination Therapy for Uncomplicated Pediatric Malaria: a Pharmacokinetic Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 2472-2484.	3.2	36
161	Feasibility of a multi-modal exercise program on cognition in older adults with Type 2 diabetes – a pilot randomised controlled trial. BMC Geriatrics, 2017, 17, 237.	2.7	36
162	Glucose Metabolism In Quinineâ€Treated Patients With Uncomplicated Falciparum Malaria. Clinical Endocrinology, 1990, 33, 739-749.	2.4	35

#	Article	IF	CITATIONS
163	The efficacy of benzimidazole drugs against Plasmodium falciparum in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 580-584.	1.8	35
164	Vascular depression in older people with diabetes. Diabetologia, 2006, 49, 2828-2836.	6.3	35
165	Sulphonylurea–metformin combination therapy, cardiovascular disease and allâ€cause mortality: the Fremantle Diabetes Study. Diabetes, Obesity and Metabolism, 2010, 12, 757-765.	4.4	35
166	Aspirin Is Associated With Reduced Cardiovascular and All-Cause Mortality in Type 2 Diabetes in a Primary Prevention Setting. Diabetes Care, 2010, 33, 317-321.	8.6	35
167	Serum Vitamin A and E Concentrations in Acute Falciparum Malaria: Modulators or Markers of Severity?. Clinical Science, 1994, 87, 505-511.	4.3	34
168	A Prospective Clinical and Bacteriologic Study of Inguinal Buboes in Thai Men. Clinical Infectious Diseases, 1996, 22, 233-239.	5.8	34
169	Protein binding and α : β anomer ratio of dihydroartemisinin in vivo. British Journal of Clinical Pharmacology, 2004, 57, 529-533.	2.4	33
170	Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes. Diabetes Care, 2012, 35, 1165-1170.	8.6	33
171	Artemisinin-Naphthoquine Combination Therapy for Uncomplicated Pediatric Malaria: a Tolerability, Safety, and Preliminary Efficacy Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 2465-2471.	3.2	33
172	Mid-Life Predictors of Cognitive Impairment and Dementia in Type 2 Diabetes Mellitus: The Fremantle Diabetes Study. Journal of Alzheimer's Disease, 2014, 42, S63-S70.	2.6	33
173	Dementia onset, incidence and risk in type 2 diabetes: a matched cohort study with the Fremantle Diabetes Study Phase I. Diabetologia, 2017, 60, 89-97.	6.3	33
174	Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. British Journal of Clinical Pharmacology, 1996, 42, 415-421.	2.4	33
175	The diagonal ear lobe crease (Frank's sign) is not associated with coronary artery disease or retinopathy in type 2 diabetes: the Fremantle Diabetes Study. Australian and New Zealand Journal of Medicine, 2000, 30, 573-577.	0.5	32
176	Incidence and Determinants of Carpal Tunnel Decompression Surgery in Type 2 Diabetes. Diabetes Care, 2008, 31, 498-500.	8.6	32
177	Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Medical Journal of Australia, 2009, 191, 47-48.	1.7	32
178	The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components?. Diabetes and Metabolism, 2015, 41, 463-469.	2.9	32
179	Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4224-4231.	3.6	32
180	The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Medicine, 2020, 17, e1003393.	8.4	32

#	Article	IF	CITATIONS
181	Relative bioavailability of artesunate and dihydroartemisinin: investigations in the isolated perfused rat liver and in healthy Caucasian volunteers American Journal of Tropical Medicine and Hygiene, 2002, 66, 130-136.	1.4	32
182	Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study. European Journal of Endocrinology, 2012, 167, 589-599.	3.7	31
183	Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial. PLoS Medicine, 2014, 11, e1001773.	8.4	31
184	Antiplasmodial and Antioxidant Isofuranonaphthoquinones from the Roots of Bulbine capitata. Planta Medica, 2001, 67, 340-344.	1.3	30
185	Treatment of Uncomplicated Falciparum Malaria in Southern Vietnam: Can Chloroquine or Sulfadoxine-Pyrimethamine Be Reintroduced in Combination with Artesunate?. Clinical Infectious Diseases, 2003, 37, 1461-1466.	5.8	30
186	A comparative study of a flow-cytometry-based assessment of in vitro Plasmodium falciparum drug sensitivity. Malaria Journal, 2009, 8, 294.	2.3	30
187	A comparison of the sensitivities of detection of Plasmodium falciparum gametocytes by magnetic fractionation, thick blood film microscopy, and RT-PCR. Malaria Journal, 2009, 8, 98.	2.3	30
188	Plasma Plasmodium falciparum Histidine-Rich Protein-2 Concentrations Do Not Reflect Severity of Malaria in Papua New Guinean Children. Clinical Infectious Diseases, 2011, 52, 440-446.	5.8	30
189	Population Pharmacokinetics, Tolerability, and Safety of Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine-Piperaquine in Pregnant and Nonpregnant Papua New Guinean Women. Antimicrobial Agents and Chemotherapy, 2015, 59, 4260-4271.	3.2	30
190	Glycerol metabolism in severe falciparum malaria. Metabolism: Clinical and Experimental, 1994, 43, 887-892.	3.4	29
191	Prevalence of abdominal aortic aneurysms in men with diabetes. Medical Journal of Australia, 1997, 166, 630-633.	1.7	29
192	Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers. British Journal of Clinical Pharmacology, 2001, 52, 377-385.	2.4	29
193	A comparison of two methods of foot health education: The Fremantle Diabetes Study Phase II. Primary Care Diabetes, 2015, 9, 155-162.	1.8	29
194	Pharmacokinetics of Transfer of Azithromycin into the Breast Milk of African Mothers. Antimicrobial Agents and Chemotherapy, 2016, 60, 1592-1599.	3.2	29
195	Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease. EuPA Open Proteomics, 2017, 14, 1-10.	2.5	29
196	Hippocampal atrophy, asymmetry, and cognition in type 2 diabetes mellitus. Brain and Behavior, 2018, 8, e00741.	2.2	29
197	A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations. Contemporary Clinical Trials, 2020, 90, 105892	1.8	29
198	Abnormal circulatory control in falciparum malaria: the effects of antimalarial drugs. European Journal of Clinical Pharmacology, 1993, 44, 325-329.	1.9	28

#	Article	IF	CITATIONS
199	Glucose metabolism in severe malaria: Minimal model analysis of the intravenous glucose tolerance test incorporating a stable glucose label. Metabolism: Clinical and Experimental, 1997, 46, 1435-1440.	3.4	28
200	Relative Bradycardia Is Not a Feature of Enteric Fever in Children. Clinical Infectious Diseases, 1999, 28, 582-586.	5.8	28
201	Subacute Sclerosing Panencephalitis in Papua New Guinean Children: The Cost of Continuing Inadequate Measles Vaccine Coverage. PLoS Neglected Tropical Diseases, 2011, 5, e932.	3.0	28
202	Validation and Application of a Dried Blood Spot Ceftriaxone Assay. Antimicrobial Agents and Chemotherapy, 2016, 60, 14-23.	3.2	28
203	Antibody Targets on the Surface of <i>Plasmodium falciparum–</i> Infected Erythrocytes That Are Associated With Immunity to Severe Malaria in Young Children. Journal of Infectious Diseases, 2019, 219, 819-828.	4.0	28
204	Dexfenfluramine in Type II diabetes: effect on weight and diabetes control. Medical Journal of Australia, 1993, 158, 167-169.	1.7	28
205	Determinants of ADP-induced platelet aggregation in diabetes mellitus. Diabetologia, 1986, 29, 291-294.	6.3	27
206	Synergistic In Vitro Antimalarial Activity of Omeprazole and Quinine. Antimicrobial Agents and Chemotherapy, 1999, 43, 1304-1306.	3.2	27
207	Asymptomatic bacteriuria as a predictor of subsequent hospitalisation with urinary tract infection in diabetic adults: The Fremantle Diabetes Study. Diabetologia, 2005, 48, 1288-1291.	6.3	27
208	Determinants of Diabetes-Attributable Non-Blood Glucose-Lowering Medication Costs in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2005, 28, 329-336.	8.6	27
209	Prognostic indicators in adults hospitalized with falciparum malaria in Western Thailand. Malaria Journal, 2013, 12, 229.	2.3	27
210	Comorbid Anxiety and Depression and Their Impact on Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Depression and Anxiety, 2016, 33, 960-966.	4.1	27
211	The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2019, 16, e1002928.	8.4	27
212	Changes in the peripheral blood eosinophil count in falciparum malaria. Acta Tropica, 1991, 48, 243-246.	2.0	26
213	The Hypothalamic-Pituitary-Adrenocortical Axis in Severe Falciparum Malaria: Effects of Cytokines1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3029-3033.	3.6	26
214	Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients. Diabetes and Vascular Disease Research, 2010, 7, 296-299.	2.0	26
215	Comparison of an assumed versus measured leucocyte count in parasite density calculations in Papua New Guinean children with uncomplicated malaria. Malaria Journal, 2014, 13, 145.	2.3	26
216	Temporal Trends in Cardiovascular Complications in People With or Without Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2471-e2482.	3.6	26

#	Article	IF	CITATIONS
217	Diabetes and metabolic dysfunction-associated fatty liver disease. Metabolism: Clinical and Experimental, 2021, 123, 154868.	3.4	26
218	Mathematical Modeling of Malaria Infection with Innate and Adaptive Immunity in Individuals and Agent-Based Communities. PLoS ONE, 2012, 7, e34040.	2.5	26
219	Prevalence and Predictors of Complementary Medicine Usage in Diabetes: Fremantle Diabetes Study. Journal of Pharmacy Practice and Research, 2003, 33, 260-264.	0.8	25
220	Calcium and phosphate metabolism in acute falciparum malaria. Clinical Science, 1991, 81, 297-304.	4.3	24
221	The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study. Internal Medicine Journal, 2006, 36, 155-161.	0.8	24
222	Pharmacokinetic Comparison of Two Piperaquine-Containing Artemisinin Combination Therapies in Papua New Guinean Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 3288-3297.	3.2	24
223	A longitudinal study of foot ulceration and its risk factors in community-based patients with type 2 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2014, 106, 42-49.	2.8	24
224	Depression symptoms are persistent in Type 2 diabetes: risk factors and outcomes of 5â€year depression trajectories using latent class growth analysis. Diabetic Medicine, 2017, 34, 1108-1115.	2.3	24
225	Safety and therapeutic efficacy of artesunate suppositories for treatment of malaria in children in Papua New Guinea. Pediatric Infectious Disease Journal, 2003, 22, 251-255.	2.0	23
226	In Vitro Interactions between Piperaquine, Dihydroartemisinin, and Other Conventional and Novel Antimalarial Drugs. Antimicrobial Agents and Chemotherapy, 2006, 50, 2883-2885.	3.2	23
227	Prevalence, Characteristics, and Prognostic Significance of <i>HFE</i> Gene Mutations in Type 2 Diabetes. Diabetes Care, 2008, 31, 1795-1801.	8.6	23
228	Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism, 2018, 20, 1427-1434.	4.4	23
229	Clinical features and management of <i>Plasmodium knowlesi</i> infections in humans. Parasitology, 2018, 145, 18-31.	1.5	23
230	Clinical Features and Outcome in Children with Severe Plasmodium falciparum Malaria: A Meta-Analysis. PLoS ONE, 2014, 9, e86737.	2.5	23
231	Antimalarial drugs and glucose metabolism. British Journal of Clinical Pharmacology, 1997, 44, 1-7.	2.4	22
232	Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisinin using rat liver perfusions and microsomes. British Journal of Pharmacology, 1998, 125, 159-167.	5.4	22
233	<i>In vitro</i> sensitivity of <i>Plasmodium falciparum</i> to conventional and novel antimalarial drugs in Papua New Guinea. Tropical Medicine and International Health, 2010, 15, 342-349.	2.3	22
234	Lumbar Puncture in Children from an Area of Malaria Endemicity Who Present with a Febrile Seizure. Clinical Infectious Diseases, 2010, 51, 534-540.	5.8	22

#	Article	IF	CITATIONS
235	Chloroquine and Its Derivatives Exacerbate B19V-Associated Anemia by Promoting Viral Replication. PLoS Neglected Tropical Diseases, 2010, 4, e669.	3.0	22
236	Apathy in Older Patients with Type 2ÂDiabetes. American Journal of Geriatric Psychiatry, 2015, 23, 615-621.	1.2	22
237	Acquisition of Antibodies Against Endothelial Protein C Receptor–Binding Domains of <i>Plasmodium falciparum</i> Erythrocyte Membrane Protein 1 in Children with Severe Malaria. Journal of Infectious Diseases, 2019, 219, 808-818.	4.0	22
238	Glucose Turnover in Pregnant Women with Acute Malaria. Clinical Science, 1994, 86, 83-90.	4.3	21
239	Retinopathy in latent autoimmune diabetes of adults: the Fremantle Diabetes Study. Diabetic Medicine, 2002, 19, 602-605.	2.3	21
240	Glucose and lactate turnover in adults with falciparum malaria: effect of complications and antimalarial therapy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2002, 96, 411-417.	1.8	21
241	Parasites and biosecurity – the example of Australia. Trends in Parasitology, 2003, 19, 410-416.	3.3	21
242	Notifications of imported malaria in Western Australia, 1990–2001: incidence, associated factors and chemoprophylaxis. Medical Journal of Australia, 2005, 182, 164-167.	1.7	21
243	Economic impact of moderate weight loss in patients with Type 2 diabetes: The Fremantle Diabetes Study. Diabetic Medicine, 2011, 28, 1131-1135.	2.3	21
244	Molecular Assessment of <i>Plasmodium falciparum</i> Resistance to Antimalarial Drugs in Papua New Guinea Using an Extended Ligase Detection Reaction Fluorescent Microsphere Assay. Antimicrobial Agents and Chemotherapy, 2011, 55, 798-805.	3.2	21
245	Pharmacokinetic Properties of Single-Dose Primaquine in Papua New Guinean Children: Feasibility of Abbreviated High-Dose Regimens for Radical Cure of Vivax Malaria. Antimicrobial Agents and Chemotherapy, 2014, 58, 432-439.	3.2	21
246	Temporal changes in the prevalence and associates of foot ulceration in type 2 diabetes: The Fremantle Diabetes Study. Journal of Diabetes and Its Complications, 2015, 29, 356-361.	2.3	21
247	Prevalence, risk factors and sequelae of Staphylococcus aureus carriage in diabetes: the Fremantle Diabetes Study Phase II. Journal of Diabetes and Its Complications, 2015, 29, 1092-1097.	2.3	21
248	Temporal Trends in Incident Hospitalization for Diabetes-Related Foot Ulcer in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2021, 44, 722-730.	8.6	21
249	Serum ionized calcium, serum and intracellular phosphate, and serum parathormone concentrations in acute malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 49-53.	1.8	20
250	Community-acquired infections in type 2 diabetic patients and their nondiabetic partners. Journal of Diabetes and Its Complications, 2005, 19, 259-263.	2.3	20
251	Helicobacter pylori cytotoxin-associated gene-A antibodies do not predict complications or death in type 2 diabetes: The Fremantle Diabetes Study. Atherosclerosis, 2010, 212, 321-326.	0.8	20
252	The relationship between estimated glomerular filtration rate trajectory and all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study. European Journal of Endocrinology, 2016, 175, 273-285.	3.7	20

#	Article	IF	CITATIONS
253	Rapid Antigen Detection Tests for Malaria Diagnosis in Severely Ill Papua New Guinean Children: A Comparative Study Using Bayesian Latent Class Models. PLoS ONE, 2012, 7, e48701.	2.5	20
254	Clinical Impact of the Temporal Relationship between Depression and Type 2 Diabetes: The Fremantle Diabetes Study Phase II. PLoS ONE, 2013, 8, e81254.	2.5	20
255	Plasma N-acetyl-?,D-glucosaminidase activities and glycaemia in diabetes mellitus. Diabetologia, 1983, 24, 433-6.	6.3	19
256	Platelet-activating factor and lipid metabolism in acute malaria. Journal of Infection, 1993, 26, 279-285.	3.3	19
257	Prospects for the treatment of drug-resistant malaria parasites. Future Microbiology, 2006, 1, 127-141.	2.0	19
258	Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC–MS assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 902, 142-146.	2.3	19
259	A histopathologic study of fatal paediatric cerebral malaria caused by mixed Plasmodium falciparum/Plasmodium vivax infections. Malaria Journal, 2012, 11, 107.	2.3	19
260	Quality of Antimalarial Drugs and Antibiotics in Papua New Guinea: A Survey of the Health Facility Supply Chain. PLoS ONE, 2014, 9, e96810.	2.5	19
261	Prevalence of depression and its associations with cardio-metabolic control in Aboriginal and Anglo-Celt patients with type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes Research and Clinical Practice, 2015, 107, 384-391.	2.8	19
262	Metabolic memory and allâ€cause death in communityâ€based patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetes, Obesity and Metabolism, 2016, 18, 598-606.	4.4	19
263	Efficacy of Intermittently Scanned Continuous Glucose Monitoring in the Prevention of Recurrent Severe Hypoglycemia. Diabetes Technology and Therapeutics, 2020, 22, 367-373.	4.4	19
264	Hyponatremia in severe malaria: evidence for an appropriate anti-diuretic hormone response to hypovolemia. American Journal of Tropical Medicine and Hygiene, 2009, 80, 141-5.	1.4	19
265	The effect of cholinergic blockade on the growth hormone response to galanin in humans. Metabolism: Clinical and Experimental, 1988, 37, 1089-1091.	3.4	18
266	The pituitary-thyroid axis in severe falciparum malaria: evidence for depressed thyrotroph and thyroid gland function. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 330-335.	1.8	18
267	Maternal Family History of Diabetes Is Associated With a Reduced Risk of Cardiovascular Disease in Women With Type 2 Diabetes. Diabetes Care, 2010, 33, 1477-1483.	8.6	18
268	Characterization of Treatment Failure in Efficacy Trials of Drugs against Plasmodium vivax by Genotyping Neutral and Drug Resistance-Associated Markers. Antimicrobial Agents and Chemotherapy, 2011, 55, 4479-4481.	3.2	18
269	Cost–effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bulletin of the World Health Organization, 2011, 89, 211-220.	3.3	18
270	Reference Intervals for Common Laboratory Tests in Melanesian Children. American Journal of Tropical Medicine and Hygiene, 2011, 85, 50-54.	1.4	18

#	Article	IF	CITATIONS
271	Population Pharmacokinetics of Intravenous Artesunate: A Pooled Analysis of Individual Data From Patients With Severe Malaria. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-9.	2.5	18
272	Prevention of bacterial infections in the newborn by pre-delivery administration of azithromycin: Study protocol of a randomized efficacy trial. BMC Pregnancy and Childbirth, 2015, 15, 302.	2.4	18
273	Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea. Malaria Journal, 2015, 14, 399.	2.3	18
274	Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. British Journal of Clinical Pharmacology, 2016, 82, 199-212.	2.4	18
275	Lifetime depression history and depression risk in type 2 diabetes: A case-control study. Journal of Diabetes and Its Complications, 2016, 30, 38-42.	2.3	18
276	The prevalence of monogenic diabetes in Australia: the Fremantle Diabetes Study Phase II. Medical Journal of Australia, 2017, 207, 344-347.	1.7	18
277	A comparison of obesity indices in relation to mortality in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia, 2020, 63, 528-536.	6.3	18
278	The Hypothalamic-Pituitary-Adrenocortical Axis in Severe Falciparum Malaria: Effects of Cytokines. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3029-3033.	3.6	18
279	CAREGIVERS' ACCEPTANCE OF USING ARTESUNATE SUPPOSITORIES FOR TREATING CHILDHOOD MALARIA IN PAPUA NEW GUINEA. American Journal of Tropical Medicine and Hygiene, 2007, 76, 634-640.	1.4	18
280	Parasitic procrastination: lateâ€presenting ovale malaria and schistosomiasis. Medical Journal of Australia, 2001, 175, 146-148.	1.7	17
281	Predictors of first stroke in Type 1 diabetes: The Fremantle Diabetes Study. Diabetic Medicine, 2005, 22, 551-553.	2.3	17
282	Prevalence, Incidence, and Prognosis of Hepatobiliary Disease in Community-Based Patients with Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1581-1588.	3.6	17
283	Gametocyte Clearance Kinetics Determined by Quantitative Magnetic Fractionation in Melanesian Children with Uncomplicated Malaria Treated with Artemisinin Combination Therapy. Antimicrobial Agents and Chemotherapy, 2015, 59, 4489-4496.	3.2	17
284	Temporal changes in Plasmodium falciparum anti-malarial drug sensitivity in vitro and resistance-associated genetic mutations in isolates from Papua New Guinea. Malaria Journal, 2015, 14, 37.	2.3	17
285	Proton Pump Inhibitors, Nephropathy, and Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2985-2993.	3.6	17
286	Risk and associates of incident hip fracture in type 1 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2017, 134, 153-160.	2.8	17
287	Comparison of artemether-lumefantrine with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in eastern Nepal. American Journal of Tropical Medicine and Hygiene, 2007, 77, 423-30.	1.4	17
288	In vitro antimalarial activity of retinoids and the influence of selective retinoic acid receptor antagonists. Acta Tropica, 2003, 87, 345-353.	2.0	16

#	Article	IF	CITATIONS
289	Statins as Potential Antimalarial Drugs: Low Relative Potency and Lack of Synergy with Conventional Antimalarial Drugs. Antimicrobial Agents and Chemotherapy, 2009, 53, 2212-2214.	3.2	16
290	Prevention and treatment of malaria in pregnancy. Future Microbiology, 2010, 5, 1599-1613.	2.0	16
291	Effect of Coadministered Fat on the Tolerability, Safety, and Pharmacokinetic Properties of Dihydroartemisinin-Piperaquine in Papua New Guinean Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2014, 58, 5784-5794.	3.2	16
292	Naphthoquine: An Emerging Candidate for Artemisinin Combination Therapy. Drugs, 2016, 76, 789-804.	10.9	16
293	Serum bicarbonate concentration and the risk of cardiovascular disease and death in type 2 diabetes: the Fremantle Diabetes Study. Cardiovascular Diabetology, 2016, 15, 143.	6.8	16
294	A 10-Year Prospective Study of Bone Mineral Density and Bone Turnover in Males and Females With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3531-3539.	3.6	16
295	Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes, Obesity and Metabolism, 2018, 20, 2852-2859.	4.4	16
296	Retinopathy predicts stroke but not myocardial infarction in type 2 diabetes: the Fremantle Diabetes Study Phase II. Cardiovascular Diabetology, 2020, 19, 43.	6.8	16
297	Severe falciparum malaria with hyperparasitaemia treated with intravenous artesunate. Medical Journal of Australia, 1997, 166, 416-418.	1.7	15
298	Assessment of the Effect of Mefloquine on Artesunate Pharmacokinetics in Healthy Male Volunteers. Antimicrobial Agents and Chemotherapy, 2007, 51, 1099-1101.	3.2	15
299	Parameterization of high magnetic field gradient fractionation columns for applications with Plasmodium falciparum infected human erythrocytes. Malaria Journal, 2010, 9, 116.	2.3	15
300	Nuclear Magnetic Resonance: A Tool for Malaria Diagnosis?. American Journal of Tropical Medicine and Hygiene, 2011, 85, 815-817.	1.4	15
301	Comparison of three methods for detection of gametocytes in Melanesian children treated for uncomplicated malaria. Malaria Journal, 2014, 13, 319.	2.3	15
302	Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. Clinical Therapeutics, 2017, 39, 1012-1025.	2.5	15
303	Platelet sensitivity in vitro to adenosine-5?-diphosphate and prostacyclin and diabetic retinopathy. Diabetologia, 1985, 28, 274-276.	6.3	14
304	Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers British Journal of Clinical Pharmacology, 1990, 30, 397-403.	2.4	14
305	Antiplatelet therapy, <i>Helicobacter pylori</i> infection and complicated peptic ulcer disease in diabetes: The Fremantle Diabetes Study. Diabetic Medicine, 2009, 26, 70-75.	2.3	14
306	Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study. Journal of Vascular Surgery, 2009, 50, 626-631.	1.1	14

#	Article	IF	CITATIONS
307	Pharmacokinetic Properties of Conventional and Double-Dose Sulfadoxine-Pyrimethamine Given as Intermittent Preventive Treatment in Infancy. Antimicrobial Agents and Chemotherapy, 2011, 55, 1693-1700.	3.2	14
308	Diagnostic Criteria for Depression in Type 2 Diabetes: A Data-Driven Approach. PLoS ONE, 2014, 9, e112049.	2.5	14
309	Intensification of medication and glycaemic control among patients with type 2 diabetes–Âthe <scp>ADVANCE</scp> trial. Diabetes, Obesity and Metabolism, 2014, 16, 426-432.	4.4	14
310	Selfâ€ a wareness of foot health status in patients with Type 2 diabetes: the Fremantle Diabetes Study Phase <scp>II</scp> . Diabetic Medicine, 2014, 31, 1439-1445.	2.3	14
311	Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study. Journal of Alzheimer's Disease, 2017, 56, 1127-1133.	2.6	14
312	Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling. International Journal of Antimicrobial Agents, 2017, 50, 542-551.	2.5	14
313	Validation of a protein biomarker test for predicting renal decline in type 2 diabetes: The Fremantle Diabetes Study Phase II. Journal of Diabetes and Its Complications, 2019, 33, 107406.	2.3	14
314	Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes. Medical Journal of Australia, 2020, 212, 133-139.	1.7	14
315	Prevalence and patterns of multimorbidity in Australian baby boomers: the Busselton healthy ageing study. BMC Public Health, 2021, 21, 1539.	2.9	14
316	Longevity of Antibody Responses to a Salmonella typhi-Specific Outer Membrane Protein: Interpretation of a Dot Enzyme Immunosorbent Assay in an Area of High Typhoid Fever Endemicity. American Journal of Tropical Medicine and Hygiene, 1997, 57, 656-659.	1.4	14
317	Meningeal Inflammation Increases Artemether Concentrations in Cerebrospinal Fluid in Papua New Guinean Children Treated with Intramuscular Artemether. Antimicrobial Agents and Chemotherapy, 2011, 55, 5027-5033.	3.2	13
318	Investigation of volatile organic biomarkers derived from Plasmodium falciparum in vitro. Malaria Journal, 2012, 11, 314.	2.3	13
319	Prevalence and prognosis of a low serum testosterone in men with type 2 diabetes: the Fremantle Diabetes Study Phase II. Clinical Endocrinology, 2016, 85, 444-452.	2.4	13
320	Prevalence and incidence of thyroid dysfunction in type 1 diabetes, type 2 diabetes and latent autoimmune diabetes of adults: The Fremantle Diabetes Study Phase II. Clinical Endocrinology, 2020, 92, 373-382.	2.4	13
321	Characterization of the effect of retinol on Plasmodium falciparum in vitro. Experimental Parasitology, 2004, 107, 136-144.	1.2	12
322	Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin. International Journal for Parasitology, 2007, 37, 1569-1576.	3.1	12
323	Ultrasonographic assessment of splenic volume at presentation and after anti-malarial therapy in children with malarial anaemia. Malaria Journal, 2015, 14, 219.	2.3	12
324	Pharmacokinetics of Piperaquine Transfer into the Breast Milk of Melanesian Mothers. Antimicrobial Agents and Chemotherapy, 2015, 59, 4272-4278.	3.2	12

#	Article	IF	CITATIONS
325	A Toll-like receptor-1 variant and its characteristic cellular phenotype is associated with severe malaria in Papua New Guinean children. Genes and Immunity, 2016, 17, 52-59.	4.1	12
326	A populationâ€based study of the association between dysglycaemia and hearing loss in middle age. Diabetic Medicine, 2017, 34, 683-690.	2.3	12
327	Penicillin Dried Blood Spot Assay for Use in Patients Receiving Intramuscular Benzathine Penicillin G and Other Penicillin Preparations To Prevent Rheumatic Fever. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	12
328	Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II. Journal of Diabetes and Its Complications, 2018, 32, 400-405.	2.3	12
329	Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: The Fremantle Diabetes Study Phase I. Diabetes Care, 2019, 42, 102-109.	8.6	12
330	Population Pharmacokinetic Study of Ceftriaxone in Elderly Patients, Using Cystatin C-Based Estimates of Renal Function To Account for Frailty. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	12
331	Incidence and associates of diabetic ketoacidosis in a community-based cohort: the Fremantle Diabetes Study Phase II. BMJ Open Diabetes Research and Care, 2020, 8, e000983.	2.8	12
332	Progression of skeletal muscle damage during treatment of severe falciparum malaria. Acta Tropica, 2000, 76, 271-276.	2.0	11
333	Cardiovascular risk factors in pre-pubertal Malays: Effects of diabetic parentage. Diabetes Research and Clinical Practice, 2007, 76, 119-125.	2.8	11
334	Investigation of reproductive toxicity of piperaquine in mice. Reproductive Toxicology, 2010, 29, 206-213.	2.9	11
335	Cryptococcal meningitis in immunocompetent Papua New Guinean children. Tropical Doctor, 2010, 40, 61-63.	0.5	11
336	Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E696-E700.	3.6	11
337	Increasing Chloramphenicol Resistance in Streptococcus pneumoniae Isolates from Papua New Guinean Children with Acute Bacterial Meningitis. Antimicrobial Agents and Chemotherapy, 2011, 55, 4454-4456.	3.2	11
338	Risk of suicide in Australian adults with diabetes: the Fremantle Diabetes Study. Internal Medicine Journal, 2015, 45, 976-980.	0.8	11
339	Pharmacokinetics of a Novel Sublingual Spray Formulation of the Antimalarial Drug Artemether in African Children with Malaria. Antimicrobial Agents and Chemotherapy, 2015, 59, 3208-3215.	3.2	11
340	A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
341	Dementia complicating type 2 diabetes and the influence of premature mortality: the Fremantle Diabetes Study. Acta Diabetologica, 2019, 56, 767-776.	2.5	11
342	Possible Neuroleptic Malignant Syndrome Associated with Olanzapine. Annals of Pharmacotherapy, 2000, 34, 667-667.	1.9	10

#	Article	IF	CITATIONS
343	Application of a multi-faceted approach for the assessment of treatment response in falciparum malaria: a study from Malaysian Borneo. International Journal for Parasitology, 2003, 33, 1545-1552.	3.1	10
344	Comparison of bioassay and high performance liquid chromatographic assay of artesunate and dihydroartemisinin in plasma. Acta Tropica, 2003, 87, 371-375.	2.0	10
345	Toxicity Related to Chloroquine Treatment of Resistant Vivax Malaria. Annals of Pharmacotherapy, 2003, 37, 526-529.	1.9	10
346	Risk factors for Plasmodium falciparum and Plasmodium vivax gametocyte carriage in Papua New Guinean children with uncomplicated malaria. Acta Tropica, 2016, 160, 1-8.	2.0	10
347	Validation and Application of a Dried Blood Spot Assay for Biofilm-Active Antibiotics Commonly Used for Treatment of Prosthetic Implant Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 4940-4955.	3.2	10
348	Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1115-1133.	3.3	10
349	Incidence and Determinants of Intraocular Lens Implantation in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care, 2019, 42, 288-296.	8.6	10
350	Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations. European Journal of Clinical Pharmacology, 2019, 75, 511-517.	1.9	10
351	The relationship between carotid disease and retinopathy in diabetes: a systematic review. Cardiovascular Diabetology, 2020, 19, 54.	6.8	10
352	Communityâ€based management of complex type 2 diabetes: adaptation of an integrated model of care in a general practice setting. Internal Medicine Journal, 2021, 51, 62-68.	0.8	10
353	CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 310-9.	0.4	10
354	Clearance of young parasite forms following treatment of falciparum malaria in humans: comparison of three simple mathematical models. Epidemiology and Infection, 1997, 119, 61-69.	2.1	9
355	Subclinical hypothyroidism and mortality in women with type 2 diabetes. Clinical Endocrinology, 2006, 64, 476-477.	2.4	9
356	Toxicology and pharmacokinetics of piperaquine in mice. Toxicology, 2008, 249, 55-61.	4.2	9
357	Predictors of Acute Bacterial Meningitis in Children from a Malaria-Endemic Area of Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2012, 86, 240-245.	1.4	9
358	Determinants and costs of community nursing in patients with type 2 diabetes from a community-based observational study: The Fremantle Diabetes Study. International Journal of Nursing Studies, 2013, 50, 1166-1171.	5.6	9
359	Influence of Premature Mortality on the Link Between Type 2 Diabetes and Hip Fracture: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 551-559.	3.6	9
360	The relationship between circulating adiponectin, ADIPOQ variants and incident cardiovascular disease in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2018, 143, 62-70.	2.8	9

#	Article	IF	CITATIONS
361	Apoptosis inhibitor of macrophage and diabetic kidney disease. Cellular and Molecular Immunology, 2019, 16, 521-521.	10.5	9
362	Risk factors and outcomes of anxiety symptom trajectories in type 2 diabetes: the Fremantle Diabetes Study Phase II. Diabetic Medicine, 2020, 37, 1688-1695.	2.3	9
363	Influence of Renin-Angiotensin System Inhibitors on Lower–Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care, 2020, 43, 2113-2120.	8.6	9
364	Pharmacokinetics of dihydroartemisinin in a murine malaria model. American Journal of Tropical Medicine and Hygiene, 2008, 78, 641-2.	1.4	9
365	Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine, 2022, 20, 85.	5.5	9
366	Glucose tolerance in rural diabetic Thais, first-degree relatives and non-diabetic controls. Diabetes Research and Clinical Practice, 1995, 27, 171-180.	2.8	8
367	Treatment of falciparum malaria in Vietnamese children: the need for combination therapy and optimized dosage regimens. Annals of Tropical Paediatrics, 2001, 21, 307-312.	1.0	8
368	Autoantibodies to the islet cell antigen SOX-13 are associated with duration but not type of diabetes. Diabetic Medicine, 2003, 20, 198-204.	2.3	8
369	The continuing legacy of the United Kingdom Prospective Diabetes Study. Medical Journal of Australia, 2004, 180, 104-105.	1.7	8
370	Greater use of insulin by southern European compared with Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study. European Journal of Endocrinology, 2004, 151, 579-586.	3.7	8
371	The mechanistic, diagnostic and prognostic utility of biomarkers in severe malaria. Biomarkers in Medicine, 2013, 7, 363-380.	1.4	8
372	Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study. Malaria Journal, 2015, 14, 121.	2.3	8
373	Circulating osteocalcin is unrelated to glucose homoeostasis in adults with type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 948-951.	2.3	8
374	Clinical risk factors for depressive syndrome in Type 2 diabetes: the Fremantle Diabetes Study. Diabetic Medicine, 2018, 35, 903-910.	2.3	8
375	Caregivers' acceptance of using artesunate suppositories for treating childhood malaria in Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2007, 76, 634-40.	1.4	8
376	Insulin sensitivity and beta-cell function assessed by C-peptide in young adults with cystic fibrosis. European Journal of Clinical Investigation, 1987, 17, 12-15.	3.4	7
377	In-vivo Platelet Activation and Anomalous Thrombospondin Levels in Severe Falciparum Malaria. Platelets, 1992, 3, 195-200.	2.3	7
378	A comprehensive patient-held record for diabetes. Part one: initial development of the Diabetes Databank. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2001, 18, 241-245.	0.2	7

#	Article	IF	CITATIONS
379	Cardiovascular risk prediction in adults with type 1 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2010, 90, e75-e78.	2.8	7
380	The relationship between self-monitoring of blood glucose results and glycated haemoglobin in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2011, 94, 371-376.	2.8	7
381	Quantification of Plasmodium falciparum Gametocytes by Magnetic Fractionation. American Journal of Tropical Medicine and Hygiene, 2011, 84, 158-160.	1.4	7
382	Plasmodium falciparum and Plasmodium vivax Genotypes and Efficacy of Intermittent Preventive Treatment in Papua New Guinea. Antimicrobial Agents and Chemotherapy, 2014, 58, 6958-6961.	3.2	7
383	Accuracy of cerebrospinal leucocyte count, protein and culture for the diagnosis of acute bacterial meningitis: a comparative study using <scp>B</scp> ayesian latent class analysis. Tropical Medicine and International Health, 2014, 19, 1520-1524.	2.3	7
384	Pharmacokinetics of a Novel Sublingual Spray Formulation of the Antimalarial Drug Artemether in Healthy Adults. Antimicrobial Agents and Chemotherapy, 2015, 59, 3197-3207.	3.2	7
385	Dose–response relationship between statin therapy and glycaemia in communityâ€based patients with type 2 diabetes: the <scp>F</scp> remantle <scp>D</scp> iabetes <scp>S</scp> tudy. Diabetes, Obesity and Metabolism, 2016, 18, 1143-1146.	4.4	7
386	Treatment regimens for pregnant women with falciparum malaria. Expert Review of Anti-Infective Therapy, 2016, 14, 691-704.	4.4	7
387	Low serum HDL-cholesterol concentrations in mid-life predict late-life cognitive impairment in type 2 diabetes: The Fremantle diabetes study. Journal of Diabetes and Its Complications, 2017, 31, 945-947.	2.3	7
388	Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review. Clinical Infectious Diseases, 2018, 66, 799-804.	5.8	7
389	Validation of a Dried Blood Spot Ceftriaxone Assay in Papua New Guinean Children with Severe Bacterial Infections. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	7
390	The relationship between intensification of blood glucose-lowering therapies, health status and quality of life in type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes Research and Clinical Practice, 2018, 142, 294-302.	2.8	7
391	Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care, 2020, 43, 3034-3041.	8.6	7
392	PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS). Journal of Clinical Medicine, 2020, 9, 3212.	2.4	7
393	Contemporary Cardiovascular Risk Assessment for Type 2 Diabetes Including Heart Failure as an Outcome: The Fremantle Diabetes Study Phase II. Journal of Clinical Medicine, 2020, 9, 1428.	2.4	7
394	Efficacy and Safety of Ertugliflozin in Patients with TypeÂ2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV. Diabetes Therapy, 2021, 12, 1279-1297.	2.5	7
395	Compliance in diabetes mellitus: A self-assessment study. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1988, 5, 170-172.	0.2	6
396	The metabolism of platelet-activating factor in severe and cerebral malaria. Journal of Infection, 1995, 31, 181-188.	3.3	6

#	Article	IF	CITATIONS
397	Pharmacokinetics of retinyl palmitate and retinol after intramuscular retinyl palmitate administration in severe malaria. Clinical Science, 2000, 99, 433-441.	4.3	6
398	Pharmacokinetics of retinyl palmitate and retinol after intramuscular retinyl palmitate administration in severe malaria. Clinical Science, 2000, 99, 433.	4.3	6
399	A comprehensive patient-held record for diabetes. Part two: Large-scale assessment of the Diabetes Databank by patients and health care workers. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2001, 18, 311-314.	0.2	6
400	An Assessment of Eligibility for Inhaled Insulin (Exubera): The Fremantle Diabetes Study. Diabetes Care, 2007, 30, 360-361.	8.6	6
401	Characteristics and prognosis of <scp>A</scp> sian patients with type 2 diabetes from a multiâ€racial <scp>A</scp> ustralian community: the <scp>F</scp> remantle <scp>D</scp> iabetes <scp>S</scp> tudy. Internal Medicine Journal, 2013, 43, 1125-1132.	0.8	6
402	Accuracy of initial clinical diagnosis of acute bacterial meningitis in children from a malaria-endemic area of Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2014, 108, 444-448.	1.8	6
403	Viral pathogens in children hospitalized with features of central nervous system infection in a malaria-endemic region of Papua New Guinea. BMC Infectious Diseases, 2014, 14, 630.	2.9	6
404	Incidence and predictors of idiopathic pulmonary fibrosis complicating <scp>Type 2</scp> diabetes: the <scp>Fremantle Diabetes Study Phase</scp> I. Internal Medicine Journal, 2021, 51, 276-279.	0.8	6
405	The utility of the Diabetes Anxiety Depression Scale in Type 2 diabetes mellitus: The Fremantle Diabetes Study Phase II. PLoS ONE, 2018, 13, e0194417.	2.5	6
406	CIGMA ASSESSMENT OF INSULIN RESISTANCE AND PANCREATIC BETA CELL FUNCTION IN THE ELDERLY. Age and Ageing, 1985, 14, 220-224.	1.6	5
407	Retinol supplementation in murine Plasmodium berghei malaria: Effects on tissue levels, parasitaemia and lipid peroxidation. International Journal for Parasitology, 2007, 37, 525-537.	3.1	5
408	A cardiac magnetic resonance imaging study of electrocardiographic Q waves in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2008, 82, 87-92.	2.8	5
409	The epidemiology and characteristics of type 2 diabetes in urban, communityâ€based young people. Internal Medicine Journal, 2010, 40, 850-854.	0.8	5
410	Apolipoprotein E genotype and mortality in Southern European and Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study. European Journal of Endocrinology, 2010, 163, 559-564.	3.7	5
411	Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study. Endocrinology, 2011, 152, 1195-1195.	2.8	5
412	Accuracy, determinants, and consequences of body weight self-perception in type 2 diabetes: the Fremantle Diabetes Study. Journal of Diabetes and Its Complications, 2011, 25, 1-6.	2.3	5
413	Prevalence and predictors of abnormal arterial function in statin-treated type 2 diabetes mellitus patients. Metabolism: Clinical and Experimental, 2012, 61, 349-357.	3.4	5
414	Prevalence and Implications of Cerebrospinal Fluid Leukocytosis in Papua New Guinean Children Hospitalized with Severe Malaria. American Journal of Tropical Medicine and Hygiene, 2013, 89, 866-868.	1.4	5

#	Article	IF	CITATIONS
415	The interactive effects of type 2 diabetes mellitus and schizophrenia on all-cause mortality: The Fremantle Diabetes Study. Journal of Diabetes and Its Complications, 2015, 29, 1320-1322.	2.3	5
416	Changes in characteristics and management of <scp>A</scp> sian and <scp>A</scp> ngloâ€ <scp>C</scp> elts with type 2 diabetes over a 15â€year period in an urban <scp>A</scp> ustralian community: The <scp>F</scp> remantle <scp>D</scp> iabetes <scp>S</scp> tudy. Journal of Diabetes, 2016, 8, 139-147.	1.8	5
417	Use of quantitative pharmacology tools to improve malaria treatments. Expert Review of Clinical Pharmacology, 2016, 9, 303-316.	3.1	5
418	Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	5
419	Pharmacotherapy for the prevention of malaria in pregnant women: currently available drugs and challenges. Expert Opinion on Pharmacotherapy, 2018, 19, 1779-1796.	1.8	5
420	Temporal changes in the incidence and predictors of severe hypoglycaemia in type 2 diabetes: The Fremantle Diabetes Study. Diabetes, Obesity and Metabolism, 2019, 21, 648-657.	4.4	5
421	High risk of early sub-therapeutic penicillin concentrations after intramuscular benzathine penicillin G injections in Ethiopian children and adults with rheumatic heart disease. PLoS Neglected Tropical Diseases, 2021, 15, e0009399.	3.0	5
422	A comparison of the clinical, laboratory and epidemiological features of two divergent subpopulations of Plasmodium knowlesi. Scientific Reports, 2021, 11, 20117.	3.3	5
423	Successful Withdrawal of Insulin Therapy After Post-Treatment Clearance of Hepatitis C Virus in a Man with Type 2 Diabetes. American Journal of Case Reports, 2017, 18, 414-417.	0.8	5
424	Glucose tolerance in pregnant patients with acute falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 666-667.	1.8	4
425	Serum lipid profiles in Malay mothers and neonates: A cross-sectional study. Journal of Paediatrics and Child Health, 1996, 32, 428-432.	0.8	4
426	Effect of an intensive education programme on clinical management of diabetic inpatients. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1996, 13, 110-114.	0.2	4
427	Non-radioisotopic glucose turnover in children with falciparum malaria and enteric fever. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 532-537.	1.8	4
428	Evidence for undetected malaria infection in non-immune Australian travellers not taking chemoprophylaxis. Acta Tropica, 2006, 99, 62-66.	2.0	4
429	In VitroAntimalarial Activity and Drug Interactions of Fenofibric Acid. Antimicrobial Agents and Chemotherapy, 2012, 56, 2814-2818.	3.2	4
430	Adapting and validating diabetes simulation models across settings: Accounting for mortality differences using administrative data. Journal of Diabetes and Its Complications, 2013, 27, 351-356.	2.3	4
431	Incidence and precipitants of hospitalization for pancreatitis in people with diabetes: the Fremantle Diabetes Study. Diabetic Medicine, 2014, 31, 913-919.	2.3	4
432	Pharmacokinetic studies of antimalarials: recent developments. Expert Review of Clinical Pharmacology, 2016, 9, 341-343.	3.1	4

#	Article	IF	CITATIONS
433	Twoâ€year audit of outcomes of pituitary surgery at an Australian teaching hospital. Internal Medicine Journal, 2017, 47, 1248-1255.	0.8	4
434	Methicillin-resistant Staphylococcus aureus in Papua New Guinea: a community nasal colonization prevalence study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 360-362.	1.8	4
435	The association between carotid disease, arterial stiffness and diabetic retinopathy in type 2 diabetes: the Fremantle Diabetes Study Phase II. Diabetic Medicine, 2021, 38, e14407.	2.3	4
436	Cognitive Impairment in People with Diabetes-Related Foot Ulceration. Journal of Clinical Medicine, 2021, 10, 2808.	2.4	4
437	A regular meal and insulin infusion regimen: its use in the treatment of acute-onset ketotic diabetes and in stabilization of poorly controlled established diabetic subjects. Diabetes Care, 1982, 5, 492-496.	8.6	4
438	An Unusual Cause of Deep Venous Thrombosis. Medical Journal of Australia, 1993, 158, 648-648.	1.7	3
439	Dynamic assessment of parathyroid function in acute malaria. Journal of Internal Medicine, 1998, 243, 349-354.	6.0	3
440	Adverse Effects of Antimalarial Prophylactic Drugs: An Important Consideration in the Risk–Benefit Equation. Annals of Pharmacotherapy, 1998, 32, 1104-1106.	1.9	3
441	Evidence for continued two-brood replication of Plasmodium falciparum in vivo during quinine treatment. Acta Tropica, 2003, 89, 41-45.	2.0	3
442	Dipeptidyl peptidaseâ€4 inhibitors and cardiovascular safety. Medical Journal of Australia, 2014, 200, 450-451.	1.7	3
443	Carotid Artery Ultrasonographic Assessment in Patients from the Fremantle Diabetes Study Phase II with Carotid Bruits Detected by Electronic Auscultation. Diabetes Technology and Therapeutics, 2014, 16, 604-610.	4.4	3
444	Confirming Cerebral Malaria Deaths in Resource-Limited Settings. American Journal of Tropical Medicine and Hygiene, 2014, 90, 192-192.	1.4	3
445	Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase <scp>II</scp> . Internal Medicine Journal, 2017, 47, 1206-1210.	0.8	3
446	Regarding "Lactation Status and Studies of Pyrimethamine Pharmacokinetics in Pregnancy― CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 730-730.	2.5	3
447	Subjective memory complaints are not increased in type 2 diabetes: A matched cohort study. Journal of Diabetes and Its Complications, 2019, 33, 424-426.	2.3	3
448	Complementary medicine use and its cost in Australians with type 2 diabetes: the Fremantle Diabetes Study Phase II. Internal Medicine Journal, 2020, 50, 944-950.	0.8	3
449	Defining the combined benefit of intermittent preventive malaria treatment in pregnancy. The Lancet Global Health, 2020, 8, e871-e872.	6.3	3
450	Updated pharmacokinetic considerations for the use of antimalarial drugs in pregnant women. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 741-758.	3.3	3

#	Article	IF	CITATIONS
451	Differences in retinopathy prevalence and progression between Anglo elt and Aboriginal Australians: The Fremantle Diabetes Study Phase II. Internal Medicine Journal, 2020, , .	0.8	3
452	Assessment of biomarkers associated with rapid renal decline in the detection of retinopathy and its progression in type 2 diabetes: The Fremantle Diabetes Study Phase II. Journal of Diabetes and Its Complications, 2021, 35, 107853.	2.3	3
453	Prevalence, Incidence and Associates of Pulmonary Hypertension Complicating Type 2 Diabetes: Insights from the Fremantle Diabetes Study Phase 2 and National Echocardiographic Database of Australia. Journal of Clinical Medicine, 2021, 10, 4503.	2.4	3
454	Bradycardia and Hypothermia Complicating Azithromycin Treatment. American Journal of Case Reports, 2017, 18, 883-886.	0.8	3
455	Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Cardiovascular Diabetology, 2022, 21, .	6.8	3
456	Plasmodium falciparum: Isolate-Specific Radiosensitivity. Experimental Parasitology, 2001, 99, 108-110.	1.2	2
457	Inhaled human insulin (Exubera \hat{A}°): its pharmacologic profile, efficacy and safety in the treatment of adults with diabetes mellitus. Expert Review of Clinical Pharmacology, 2008, 1, 13-25.	3.1	2
458	Contemporary management of type 2 diabetes: blood glucose″owering therapies and glycaemic targets. Medical Journal of Australia, 2008, 189, 246-248.	1.7	2
459	Manufacture and Testing of a High Field Gradient Magnetic Fractionation System for Quantitative Detection of Plasmodium falciparum Gametocytes. , 2010, , .		2
460	Renin–angiotensin–aldosterone system blockade and urinary albumin excretion in communityâ€based patients with Type 2 diabetes: The Fremantle Diabetes Study. Diabetic Medicine, 2011, 28, 849-855.	2.3	2
461	Hypertriglyceridaemia in statinâ€ŧreated type 2 diabetic patients. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2011, 28, 257-260.	0.2	2
462	Lung function, diabetes and the metabolic syndrome. Practical Diabetes, 2014, 31, 184-185.	0.3	2
463	Updated prevalence of monogenic diabetes in Australia: Fremantle Diabetes Study Phase 2. Medical Journal of Australia, 2019, 211, 189.	1.7	2
464	Complementary and alternative medicine beliefs in type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes Research and Clinical Practice, 2020, 166, 108311.	2.8	2
465	Knowledge of ocular complications of diabetes in community-based people with type 2 diabetes: The Fremantle Diabetes Study II. Primary Care Diabetes, 2021, 15, 554-560.	1.8	2
466	The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with <i>Plasmodium knowlesi</i> malaria. British Journal of Clinical Pharmacology, 2022, 88, 691-701.	2.4	2
467	Artemisinins. , 2010, , 2090-2104.		2
468	Fenofibrate and Impaired Taste Perception in Type 2 Diabetes. American Journal of Case Reports, 2020, 21, e927647.	0.8	2

#	Article	IF	CITATIONS
469	Loss-of-function mutations in IGSF1 cause a novel, X-linked syndrome of central hypothyroidism and testicular enlargement. Endocrine Abstracts, 0, , 1-1.	0.0	2
470	Pharmacokinetic properties of the antimalarial combination therapy artemether–lumefantrine in normal-weight, overweight and obese healthy male adults. International Journal of Antimicrobial Agents, 2022, 59, 106482.	2.5	2
471	Sodiumâ€glucose cotransportâ€2 inhibitor induced ketoacidosis following coronary artery bypass surgery: implications for management. Internal Medicine Journal, 2022, 52, 876-879.	0.8	2
472	Recognition and management of falciparum malaria. EMA - Emergency Medicine Australasia, 2000, 12, 276-284.	1.1	1
473	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 251-255.	2.0	1
474	Multisystem Schistosoma haematobium Infection in an Australian Tourist. Journal of Travel Medicine, 2006, 8, 325-328.	3.0	1
475	A Clinical Screening Tool Identifies Autoimmune Diabetes in Adults: Response to Fourlanos et al Diabetes Care, 2006, 29, 2560-2560.	8.6	1
476	Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?. Medical Journal of Australia, 2009, 191, 356-357.	1.7	1
477	Rosiglitazone and cardiovascular disease revisited. Medical Journal of Australia, 2010, 193, 134-135.	1.7	1
478	O5-03-03: SEVERE HYPOGLYCAEMIA DOES NOT EXPLAIN THE RELATIONSHIP BETWEEN LONG DURATION INSULIN THERAPY AND LATE-LIFE COGNITIVE IMPAIRENT IN TYPE 2 DIABETES: THE FREMANTLE DIABETES STUDY. , 2014, 10, P295-P295.		1
479	Re: Essential Service Standards for Equitable National Cardiovascular Care for Aboriginal and Torres Strait Islander People. Heart Lung and Circulation, 2015, 24, 626.	0.4	1
480	Cost-effectiveness of artemisinin–naphthoquine versus artemether–lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children. Malaria Journal, 2017, 16, 438.	2.3	1
481	Hearing Loss in Adults. New England Journal of Medicine, 2018, 378, 968-970.	27.0	1
482	The LEADER trial in type 2 diabetes: Were the characteristics and outcomes of the participants representative?. Journal of Diabetes and Its Complications, 2019, 33, 427-433.	2.3	1
483	Changes in the Epidemiology of Hepatobiliary Disease Complicating Type 2 Diabetes over 25 Years: The Fremantle Diabetes Study. Journal of Clinical Medicine, 2020, 9, 3409.	2.4	1
484	Incidence and predictors of vision loss complicating type 2 diabetes: The Fremantle Diabetes Study Phase II. Journal of Diabetes and Its Complications, 2020, 34, 107560.	2.3	1
485	Relative incidence and predictors of pulmonary arterial hypertension complicating type 2 diabetes: The Fremantle Diabetes Study Phase I. Journal of Diabetes and Its Complications, 2021, 35, 107773.	2.3	1

#	Article	IF	CITATIONS
487	A prospective six-month audit of inpatient hypoglycemia in step-down general medical and geriatric wards. International Journal of Medical Sciences, 2021, 18, 3744-3747.	2.5	1
488	Proguanil and Chloroproguanil. , 2010, , 2082-2089.		1
489	Correlation between density of malaria parasitaemia and clinical symptoms. Medical Journal of Australia, 1995, 162, 670-670.	1.7	1
490	PHARMACOKINETIC STUDY OF INTRAMUSCULAR ARTESUNATE IN VIETNAMESE PATIENTS WITH FALCIPARUM MALARIA Therapeutic Drug Monitoring, 1999, 21, 453.	2.0	1
491	Contribution of Malaria to Inhospital Mortality in Papua New Guinean Children from a Malaria-Endemic Area: A Prospective Observational Study. American Journal of Tropical Medicine and Hygiene, 2019, 100, 835-841.	1.4	1
492	Temporal Trends in Renal Replacement Therapy in Community-Based People with or without Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Medicine, 2022, 11, 695.	2.4	1
493	Prevalence and predictors of Helicobacter pylori infection in children and adults from the Penan ethnic minority of Malaysian Borneo. American Journal of Tropical Medicine and Hygiene, 2004, 71, 444-50.	1.4	1
494	High mean platelet volume after myocardial infarction. BMJ: British Medical Journal, 1985, 290, 238-238.	2.3	0
495	Models of parasite clearance following treatment of falciparum malaria in humans. Environmetrics, 1995, 6, 529-534.	1.4	0
496	United Kingdom Prospective Diabetes Study: the end of the beginning?. Medical Journal of Australia, 1998, 169, 511-512.	1.7	0
497	Are ear lobe creases a reliable predictor of CHD?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2003, 20, 170-170.	0.2	0
498	Addition of artesunate to standard antimalarial drugs reduces treatment failure. Evidence-Based Healthcare and Public Health, 2004, 8, 156-158.	0.0	0
499	Fenofibrate and diabetic retinopathy – Authors' reply. Lancet, The, 2008, 371, 722.	13.7	0
500	Fenofibrate improves endothelial function in both conduit and resistance arteries in statin-treated type 2 diabetics. Heart Lung and Circulation, 2009, 18, S242.	0.4	0
501	Niacin improves microcirculatory endothelial dysfunction and arterial compliance in statin-treated type 2 diabetic subjects. Heart Lung and Circulation, 2009, 18, S245.	0.4	0
502	Response to Wang and Kao. American Journal of Gastroenterology, 2010, 105, 224-225.	0.4	0
503	Use of non-prescription therapies, including complementary medicines, in type 2 diabetes: the Fremantle diabetes study. International Journal of Pharmacy Practice, 2011, 10, R19-R19.	0.6	0
504	Safety of incretinâ€based therapies for type 2 diabetes. Medical Journal of Australia, 2011, 195, 312-313.	1.7	0

#	Article	IF	CITATIONS
505	Re: Subclinical thyroid dysfunction and mortality in type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1474.	2.3	0
506	Temporal changes in glycaemic thresholds for treatment intensification in type 2 diabetes in an urban Australian setting: the Fremantle Diabetes Study. Internal Medicine Journal, 2018, 48, 1215-1221.	0.8	0
507	Author reply. Internal Medicine Journal, 2018, 48, 367-368.	0.8	0
508	Response to Letter to the Editor: "Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men― Journal of Clinical Endocrinology and Metabolism, 2019, 104, 684-685.	3.6	0
509	Response to Comment on Davis et al. Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: the Fremantle Diabetes Study Phase I. Diabetes Care 2018;42:102–109. Diabetes Care, 2019, 42, e101-e101.	8.6	0
510	Diabetes in the coronary care unit. , 2011, , 606-610.		0
511	Cerebral Malaria: Pathophysiology of Clinical Features. , 2014, , 1-10.		0
512	AIDS in Thailand. Medical Journal of Australia, 1991, 154, 706-706.	1.7	0
513	Tesaglitazar. IDrugs: the Investigational Drugs Journal, 2005, 8, 927-35.	0.7	0
514	Title is missing!. , 2020, 17, e1003393.		0
515	Title is missing!. , 2020, 17, e1003393.		0
516	Title is missing!. , 2020, 17, e1003393.		0
517	Title is missing!. , 2020, 17, e1003393.		0
518	Title is missing!. , 2020, 17, e1003393.		0
519	The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children. International Journal for Parasitology: Drugs and Drug Resistance, 2022, 19, 31-39.	3.4	0